These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 28679772)
1. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Riethdorf S; Müller V; Loibl S; Nekljudova V; Weber K; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Schem C; von Minckwitz G; Untch M; Pantel K Clin Cancer Res; 2017 Sep; 23(18):5384-5393. PubMed ID: 28679772 [No Abstract] [Full Text] [Related]
2. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W; BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743 [TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845 [TBL] [Abstract][Full Text] [Related]
4. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653 [TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129 [TBL] [Abstract][Full Text] [Related]
6. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903 [TBL] [Abstract][Full Text] [Related]
7. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830 [TBL] [Abstract][Full Text] [Related]
8. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204 [TBL] [Abstract][Full Text] [Related]
9. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503 [TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591 [TBL] [Abstract][Full Text] [Related]
11. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. Goodman CR; Seagle BL; Friedl TWP; Rack B; Lato K; Fink V; Cristofanilli M; Donnelly ED; Janni W; Shahabi S; Strauss JB JAMA Oncol; 2018 Aug; 4(8):e180163. PubMed ID: 29800954 [TBL] [Abstract][Full Text] [Related]
12. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259 [TBL] [Abstract][Full Text] [Related]
13. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Janni WJ; Rack B; Terstappen LW; Pierga JY; Taran FA; Fehm T; Hall C; de Groot MR; Bidard FC; Friedl TW; Fasching PA; Brucker SY; Pantel K; Lucci A Clin Cancer Res; 2016 May; 22(10):2583-93. PubMed ID: 26733614 [TBL] [Abstract][Full Text] [Related]
14. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Riethdorf S; Müller V; Zhang L; Rau T; Loibl S; Komor M; Roller M; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Eidtmann H; Untch M; von Minckwitz G; Pantel K Clin Cancer Res; 2010 May; 16(9):2634-45. PubMed ID: 20406831 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662 [TBL] [Abstract][Full Text] [Related]
16. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110 [TBL] [Abstract][Full Text] [Related]
17. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841 [TBL] [Abstract][Full Text] [Related]
18. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222 [TBL] [Abstract][Full Text] [Related]
19. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347 [TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]